SCHEMBL24314268

SCHEMBL24314268

COc1ccc(CNc2ncnc3c2c(Br)cn3[C@@H]2C[C@H](C=O)[C@H]3OC(C)(C)O[C@H]32)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 18/20 0.39
▸ CYP3A4 P08684 18/20 0.39
▸ CYP2C19 P33261 18/20 0.39
▸ CYP2D6 P10635 16/20 0.39
▸ TSHR P16473 14/20 0.39
▸ ALDH1A1 P00352 11/20 0.39
▸ CLK4 Q9HAZ1 9/20 0.39
▸ USP2 O75604 5/20 0.39
▸ HSD17B10 Q99714 9/20 0.39
▸ ALOX15 P16050 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ CYP2C9 P11712 9/20 0.38
▸ MAPK1 P28482 6/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ LMNA P02545 6/20 0.37
▸ HIF1A Q16665 4/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29610876 1.00 CYP1A2 (0.39) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24314265 0.88 CYP1A2 (0.38) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL29610884 0.88 CYP1A2 (0.38) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL29611134 0.85 CYP1A2 (0.36) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24314272 0.85 CYP1A2 (0.36) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL29610942 0.85 CYP1A2 (0.36) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24314273 0.83 PRMT5 (0.38) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL29611556 0.83 PRMT5 (0.38) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL24313565 0.81 ADORA3 (0.43) CYP1A2CYP3A4CYP2C19CYP2D6TSHR
SCHEMBL29611653 0.81 ADORA3 (0.43) CYP1A2CYP3A4CYP2C19CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051985-A1 METTL3 MODULATORS ACCENT THERAPEUTICS INC (US) 2024-02-15 — — US disclosed
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051985-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 CYP1A2 1036/4885CYP3A4 426/4885CYP2C19 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback